drugset / Trial / NCT00766831

An Efficacy and Safety Study of Hydromorphone Oral Osmotic System (OROS) in Korean Participants With Cancer Pain

NCT00766831

Phase 4 Completed 190 enrolled Janssen Korea, Ltd., Korea
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this is study to evaluate improvement of sleep disorder caused by cancer pain after the administration of Hydromorphone Oral Osmotic System (OROS) in Korean participants with cancer.

Timeline

Start
2008-10
Primary completion
2010-06
Completion
2010-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydromorphone Other / unclassified 8 mg Oral
Subject Hydromorphone Other / unclassified 32 mg Oral

Indications

No indication recorded.